Dr. Eddy Anglade joined the company in January 2014 as the Company’s Executive Vice President of Clinical Development. From 2006 until 2013, Dr. Anglade was Chief Medical Officer and Co-Founder of Lux Biosciences, Inc., a privately held development stage biotechnology company whose therapeutic focus included ophthalmic diseases with high and unmet medical needs, including non-infectious posterior uveitis, high risk corneal transplantation and dry eye disease. As Chief Medical Officer at Lux, his responsibilities included leadership of clinical development, regulatory strategy and safety for all of its clinical programs. Prior to joining Lux Biosciences, Dr. Anglade was Vice President of Clinical Development at Enzon Pharmaceuticals, Inc. with responsibility for clinical development of its oncology and immunology portfolio. He started his career in the pharmaceutical industry at Hoffmann-LaRoche, Inc. as a Medical Director in its Transplantation and Virology Specialty Care franchises.
Dr. Anglade completed his ophthalmology residency at the Massachusetts Eye and Ear Infirmary/Harvard Medical School with further specialty training in ocular inflammation at the National Eye Institute/National Institutes of Health and received his medical degree from the Yale University School of Medicine. He received his AB at Columbia University.